CSRXP: 117TH CONGRESS TAKES FIRST STEP ON LOWERING PRESCRIPTION DRUG PRICES, HOLDING BIG PHARMA ACCOUNTABLE

Lawmakers Pass Pair of Bills Aimed at Boosting Generic and Biosimilar Competition

Washington, D.C. – The Campaign for Sustainable Rx Pricing (CSRxP) issued a statement Thursday applauding the passage of the Ensuring Innovation Act and the Advancing Education on Biosimilars Act of 2021 in the U.S. House of Representatives on Wednesday. Both bills passed out of the U.S. Senate earlier this month.

“Members of the 117^th Congress have taken an important first step to boost generic and biosimilar competition in order to deliver more affordable options for American patients,” said CSRxP executive director Lauren Aronson. “We applaud lawmakers for advancing these bipartisan, market-based solutions that will help crack down on Big Pharma’s abuse of the patent system and emphasize the importance of competition to lower prescription drug prices.”

Learn more about market-based solutions to hold Big Pharma accountable and lower prescription drug prices HERE.